Paradigm Receives $5.75m R&D Tax Incentive Refund
Filed with ASX · · 2 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Drawdown of Tranche 4 under the Convertible Note Facility
- PAR Completes Enrolment in Pivotal Phase 3
- Results of Share Purchase Plan
- DSMB 20% Review Supports Phase 3, Moldova Activated
- March 2026 Quarterly Activities Report & Appendix 4C
Later from Paradigm Biopharmaceuticals
- June 2026 Quarterly Activities Report & Appendix 4C
- Appendix 4E and 2026 Annual Report
- Suspension from Quotation
- Phase 3 Interim Result Below Continuation Threshold
- Agreement to Return US$2M to Obsidian
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals